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Abstract
Epoxides derived from arachidonic acid (AA) are released during exercise and
may contribute to vasodilation. However, exercise may also affect circulating
levels of other epoxides derived from cytochromes P450 (CYP) monooxygenase
and lipoxygenase (LOX) pathways, many of whose exhibit cardiovascular activ-
ity in vitro. The effects of exercise on their levels have not been documented.
We tested the hypothesis that acute, maximal exercise would influence the
plasma concentrations of these vasoactive substances. We measured plasma
CYP and LOX mediators derived from both the n  3 and n  6 fatty acid
(FA) classes in healthy volunteers before, during and after short-term exhaus-
tive exercise. Lipid mediators were profiled by means of LC–MS/MS tandem
mass spectrometry. A maximal Bruce treadmill test was performed to voluntary
exhaustion. Exhaustive exercise increased the circulating levels of epoxyoctade-
cenoic (12,13-EpOME), dihydroxyeicosatrienoic (5,6-DHET), dihydroxye-
icosatetraenoic acids (5,6-DiHETE, 17,18-DiHETE), but had no effect on the
majority of CYP and LOX metabolites. Although our calculations of diol/epox-
ide ratios revealed preferred hydrolysis of epoxyeicosatrienoic acids (EEQs)
into their diols (DiHETEs), this hydrolysis was resistant to maximal exercise.
Our study is the first documentation that bioactive endogenous n  3 and
n  6 CYP lipid mediators are released by short-term exhaustive exercise in
humans. In particular, the CYP epoxy-metabolite status, 12,13-EpOME/
DiHOME, 5,6-EET/DHET, 5,6-EEQ/DiHETE and 17,18-EEQ/DiHETE may
contribute to the cardiovascular response during maximal exercise.
Introduction
Vasoactive substances, including prostaglandins, nitric
oxide (NO), adenosine, adenosine 50-triphosphate (ATP),
are released from contracting skeletal muscle and vascular
endothelium and may contribute to vascular relaxation
(Clifford and Hellsten 2004). However, other vasoactive
substances may also be involved. In this regard, arachi-
donic acid (AA) can be converted into vasoactive metabo-
lites via the cytochromes P450 (CYP) mono-oxygenase
and lipoxygenase (LOX) pathways (Fig. 1). In particular,
the CYP pathway converts AA into four distinct
epoxyeicosatrienoic acid (EET) regio-isomers, namely
5,6-, 8,9-, 11,12- and 14,15 EET (epoxides). EETs can
cause hyperpolarization of smooth muscle cells and relax-
ation by opening of Ca2+-activated K+ (BK) channels
(Zhu et al. 1995; Spector 2009). Activation of this path-
way is partially or totally unresponsive to inhibitors of
cyclo-oxygenases that metabolize AA to 5-, 12, and 15-hy-
droxyeicosatetraenoic acid (HETE) (Fig. 1), prostaglan-
dins, prostacyclin (PGI2), thromboxane and leukotrienes
and inhibitors of NO synthase (Bauersachs et al. 2002;
ª 2019 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
The Physiological Society and the American Physiological Society.
This is an open access article under the terms of the Creative Commons Attribution License,
which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
2019 | Vol. 7 | Iss. 13 | e14165
Page 1
Physiological Reports ISSN 2051-817X
Busse et al. 2002). Based on these properties, EETs are
considered candidates for endothelium-derived hyperpo-
larizing factors (EDHFs) (Campbell et al. 1996), whose
release is triggered by Ca2+-induced activation of the CYP
pathway (Graber et al. 1997) and shear stress (Campbell
and Fleming 2010).
It has been suggested that EDHFs can contribute to
increases in skeletal muscle blood flow that occur during
exercise (Hillig et al. 2003). These properties could be
essential to counteract the vasoconstrictor effects of con-
current increases in muscle sympathetic nerve activity and
circulating vasoconstrictor substances during exercise.
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Figure 1. Cytochrome P450 epoxygenase (CYP) and 12- and 15-lipoxygenase (LOX)/CYP (omega-1)-hydroxylase pathways. Linoleic (LA),
arachidonic (AA), eicosapentaenoic (EPA) and docosahexaenoic acids (DHA) are converted into epoxyoctadecanoic acids (EpOMEs, e.g., 12,13-
EpOME), epoxyeicosatrienoic acid (EETs), epoxyeicosatrienoic acids (EEQs) and epoxydocosapentaenoic acids (EDPs) by CYP, respectively.
EpOMEs, EETs, EEQs, and EDPs primary metabolic fate its conversion into the dihydroxyoctadecanoic acids (DiHOMEs), dihydroxyeicosatrienoic
acids (DHETs, e.g. 5,6-DHET), dihydroxyeicosatetraenoic acids (DiHETEs, e.g. 5,6-DiHETE, 17,18-DiHETE) and dihydroxydocosapentaenoic acids
(DiHDPAs), respectively, by the soluble epoxide hydrolase (sEH) enzyme. LA, AA, EPA, and DHA are converted to hydroperoxylinoleic acids
(HpODEs), hydroxyoctadecadienoic acids (HODEs), leukotriene B (LTB), lipoxin A (LXA), hydroxydocosahexaenoic acids (HDHAs),
hydroperoxyeicosatetraenoic acids (HPETEs) and hydroxyeicosatetraenoic acids (HETEs) by LOX, CYP omega/(omega-1)-hydroxylase and
peroxidase pathways. The metabolites measured within these pathways track the changes observed in LA, AA, EPA and DHA, respectively.
Arrows demarcate metabolic pathways evaluated in response to short-term maximal exercise.
2019 | Vol. 7 | Iss. 13 | e14165
Page 2
ª 2019 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
The Physiological Society and the American Physiological Society.
Exercise and Circulating Epoxy-Metabolites B. Gollasch et al.
EETs are attractive mediator signals in this scenario
(Campbell and Fleming 2010). In addition, dihydroxye-
icosatrienoic acids (DHETs, diols), the stable metabolites
of EETs produced by soluble epoxide hydrolase (Fig. 1),
have been identified to cause vasodilation in some regio-
nal circulations, for example, the heart (Federation for
Laboratory Animal Science Associations, XXXX). Beside
AA, other n  3 and n  6 fatty acids (FA) are metabo-
lized by CYP and LOX pathways to bioactive substances
(Fig. 1). As such, linoleic acid (LA) is metabolized to
epoxyoctadecanoic acids (EpOMEs) by CYP epoxygenases
and further to dihydroxyoctadecanoic acids (DiHOMEs)
by soluble epoxide hydrolase, which may play an impor-
tant role in cardiac ischemic events (Bannehr et al. 2019).
Eicosapentaenoic acid (EPA) is metabolized to epoxye-
icosatetraenoic acids (EEQs), which can also cause hyper-
polarization of vascular smooth muscle cells and
relaxation by opening BK channels (Hercule et al. 2009).
Other candidates are epoxides, and diols produced from
the actions of lipoxygenases (LOXs), CYPs, and epoxide
hydrolases using unsaturated FAs from other n  3 [e.g.,
alpha-linolenic (aLA)] and n  6 [e.g., linoleic (LA),
dihomo- alpha-linolenic (dgLA), arachidonic (AA)] series
as substrates (Fig. 1). Thus, increases in their concentra-
tions during exercise may also contribute to correspond-
ing increases in blood flow and cardiovascular response.
Although the effects of dietary EPA/docosahexaenoic
acid (DHA) supplementation on plasma CYP-eicosanoid
profile have been reasonably well described (Fischer et al.
2014), reports of circulating levels of CYP metabolites in
response to exercise in humans are rare and have been
focused only on AA metabolites (i.e., EETs and DHETs)
(Giordano et al. 2011). Giordano et al. (2011) found that
submaximal exercise testing on a bicycle ergometer caused
an increase in plasma levels of 8,9-DHET, 11,12-DHET
and 14,15-DHET. However, the effects of short-term
maximal exercise on a wide array of n  6 and n  3
metabolites remain unreported to the best of our knowl-
edge. In this study, we tested the hypothesis that exhaus-
tive exercise would influence plasma concentrations of
epoxides derived from cytochromes P450 (CYP)
monooxygenase and lipoxygenase (LOX) pathways.
Methods
Prior to participation in the study six healthy volunteers
(5 male and 1 female; age 38  15 years; body mass
index 27.9  6.6 kg/m2) signed informed consent forms
which outlined the procedures to be taken and the possi-
ble risks involved (Gollasch et al. 2019). The study was
approved by the Charite University Medicine institutional
review board on the use of humans in research. All sub-
jects were nontrained. They were not taking medications.
Recruitment was primarily via person-to-person inter-
view. Following a routine physical examination at baseline
levels each subject underwent a maximal treadmill Bruce
test according to guidelines of the German Society of Car-
diology (Bruce et al. 1973; Trappe and Lollgen 2000). The
test was preceded by 2 9 3 min warm up periods (stages
1 and 2 of the Bruce protocol), during which treadmill
speed was maintained at a constant speed of 2.7 km/h
and at zero or 5% grade as shown in Table S1. Treadmill
speed and grade were then increased at 3-min intervals.
The test was terminated when the subjects informed the
investigator that they could no longer proceed. Workload
was assessed in metabolic equivalents (METs) as shown
in Table S1.
Heart rates were monitored continuously by the heart-
rate monitor worn around the subject’s torso (Polar T31,
Polar Electro, Kempele, Finland) throughout the tests.
Arterial pressure was measured in each subject while sit-
ting prior to the exercise test (10 min), after termina-
tion of the test (exhaustion), and 10 min recovery after
the end of the running test via a sphygmomanometer
(Critikon, Inc., Johnson & Johnson, New Jersey, USA),
which comprised an inflatable (Riva-Rocci) cuff placed
around the upper arm. Venous blood was collected from
a catheter placed in a contralateral forearm vein (i.e., the
antecubital vein) of each subject in the sitting position
prior to the exercise test (10 min), after termination of
the test (exhaustion), and 10 min recovery after the end
of the running test (Fig. 2). An additional blood sample
was collected in each subject during running when the
heart rate reached 150 beats per minute. We did not
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Figure 2. Schematic illustration of the standard Bruce protocol
used. HF, heart rate; BP, blood pressure; eicosanoid fatty acids;
METs, metabolic equivalents of task. P1 (rest), P2, P3 (peak,
exhaustion), P4 (recovery); time points used to measure HF, BP,
eicosanoid lipid profiles, lactate.
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measure blood pressure at this time point (HF 150)
because valid blood pressure measurements could not be
obtained during running using the above sphygmo-
manometer. All samples were analyzed for plasma eicosa-
noids. Red blood cells (RBCs) were separated from EDTA
blood by centrifugation and eicosanoids in plasma were
determined by liquid chromatography mass (HPLC-MS)
spectrometry described in (Fischer et al. 2014). Serum
lactate was determined in blood samples obtained from
ear lobe at rest and at maximal workload.
We performed sample size calculation for a difference
in means in DHETs (Giordano et al. 2011). We found
that our study would require a sample size of 6 (number
of pairs) to achieve a power of 80% and a level of signifi-
cance of 5% (two sided), for detecting a mean of the dif-
ferences of 0.15 between pairs (8,9-DHET), assuming the
standard deviation of the differences to be 0.09 (Giordano
et al. 2011).
Descriptive statistics were calculated and variables were
examined for meeting assumptions of normal distribution
without skewness and kurtosis. In order to determine sta-
tistical significance between the trials at the various time
intervals, one-way repeated measures analysis of variance
(ANOVA) was conducted and the 0.05 level of signifi-
cance (P) was chosen. The analysis included Mauchly’s
test of sphericity followed by applying the test of within
subjects effects with Greenhouse–Geisser correction to
ensure sphericity assumption. When significant differences
were found, Tukey’s honestly significant difference post
hoc test was used for pairwise comparisons. Planned
hypotheses (one-tailed or two-tailed paired t-tests as
appropriate) were tested to follow up the initial ANOVA
findings.
All data are presented as mean  SD. All statistical
analyses were performed using SPSS Statistics software
(IBM Corporation, Armonk, NY) or All-Therapy statistics
beta (AICBT Ltd, Vancouver, Canada).
Results
Hemodynamics
Figure 3 shows the results on the effects of acute exercise
on heart frequency and blood pressure. The values include
measurements prior to the exercise test (10 min, P1),
after termination of the test (exhaustion, P3), and 10 min
after the end of the running test (recovery period, P4). An
additional blood sample was collected in each subject dur-
ing running when the heart frequency reached 150 beats
per minute (P2) (Gollasch et al. 2019). At maximal work-
load, heart rate, and systolic blood pressure increased from
71  10 (baseline) to 185  6 beats per minute and from
135.3  9.1 to 190.3  16.6 mmHg, respectively (P <
0.0001 each, t-tests). Diastolic blood pressure did not
change (81.2  14.4 vs. 90.7  16.4 mmHg, P > 0.05).
Maximal workload occurred at 13.50  1.97 METs (P3) in
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Figure 3. Effects of short-term exhaustive exercise on hemodynamics. Means  SD at time points P1 (rest), P3 (exhaustion), P4 (recovery).
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the individuals. The corresponding Bruce stage was
6.33  0.82. Lactate levels increased from
1.38  0.30 mmol/L at rest (P1) to 9.49  2.10 mmol/L
at exhaustion (P3) (P < 0.0001, t-test), which is consistent
with a robust metabolic response leading to significant lac-
tate acidosis (Gollasch et al. 2019).
CYP and LOX mediators
Since the impact of acute exercise on circulating n  3
and n  6 CYP and LOX-mediator levels is unknown, we
used an explorative statistical approach on measured free
CYP- and LOX-dependent metabolites. We first measured
the individual-free metabolites in plasma at different time
points: rest (baseline), the time when heart rate reached
150 beats per min, exhaustion and recovery. The results
are presented in Table 1. Our ANOVA analysis showed
that there were differences in the levels of 12,13-EpOME.
In contrast, we did not detect changes in other CYP
metabolites, such as 9,10-EpOME, epoxyeicosatrienoic
acids (5,6-EET, 8,9-EET, 11,12-EET, 14,15-EET), epoxye-
icosatetraenoic acids (5,6-EEQ, 8,9-EEQ, 11,12-EEQ,
14,15-EEQ) and epoxydocosapentaenoic acids (7,8-EDP,
10,11-EDP, 13,14-EDP, 16,17-EDP, 19,20-EDP) (Table 1).
There were also no changes in the LOX metabolites
hydroxyeicosapentaenoic acids (5-HEPE, 8-HEPE, 9-
HEPE, 12-HEPE, 15-HEPE, 18-HEPE), hydroxyeicosate-
traenoic acids (5-HETE, 8-HETE, 9-HETE, 11-HETE, 12-
HETE, 15-HETE), hydroxydocosahexaenoic acids (4-
HDHA, 7-HDHA, 8-HDHA, 10-HDHA, 11-HDHA, 13-
HDHA, 14-HDHA, 16-HDHA, 17-HDHA, 20-HDHA,
21-HDHA) and 13-hydroxyoctadecadienoic acid (13-
HODE) (Table 1).
Their diols
As shown in Figure 1, the main pathway of EET, EpOME,
EEQ, and EDP metabolism in many cells and its conver-
sion to DHETs, DiHOMEs, dihydroxyeicosatetraenoic
acids (DiHETEs) and dihydroxydocosapentaenoic acids
(DiHDPAs) by the soluble epoxide hydrolase enzyme
(sEH) (Spector et al. 2004). Since acute exercise might
have caused EET, EpOME, EEQ, and EDP production
rapidly degraded to their diols, we analyzed the individual
levels (Table 1) and the sums of the individual EETs,
EpOMEs, EEQs, and EDPs and their respective diols
(Table 2). We found that exercise changed 5,6-DHET,
5,6-DiHETE and 17,18-DiHETE levels (Table 1). In con-
trast, exhaustive exercise did not change the levels of 8,9-
DHET, 14,15-DHETE, 9,10-DiHOME, 12,13-DiHOME,
5,6-DiHETE, 8,9-DiHETE, 14,15-DiHETE, 17,18-DiHETE,
7,8-DiHDPA, 10,11- DiHDPA, 13,14- DiHDPA, 16,17-
DiHDPA, and 19,20- DiHDPA (Table 1). We found that
exercise increased the levels of 12,13-EpOME plus 12,13-
DiHOME (12,13-EpOME/DiHOME), 5,6-EET plus 5,6-
DHET (5,6-EET/DHET), 8,9-EET plus 8,9-DHET (8,9-
EET/DHET), and 5,6-EEQ plus 5,6-DiHETE (5,6-EEQ/
DiHETE) levels, but not of the majority of metabolites
(Table 2).
A previous study found that submaximal testing on a
bicycle ergometer caused an ~11% increase in plasma
levels of 14,15-DHET in circulating venous blood without
affecting levels of 8,9-DHET, 11,12-DHET and respective
EETs (Giordano et al. 2011). Using the maximal Bruce
treadmill test, we found a similar (12%) increase in 5,6-
DHET (from 3.10  0.81 to 3.46  0.92 lg/mL,
P < 0.05, t-test), but not in other DHETs, in Table 1. In
addition, we found that exhaustive exercise increased
12,13-EpOME levels by ~35% (from 31.90  10.35 to
42.91  12.12 lg/mL, P < 0.05, t-test) and 5,6-DiHETE
and 17,18-DiHETE by ~25% each (from 0.99  0.42 to
1.22  0.43 lg/mL and from 1.07  0.13 to
1.29  0.23 lg/mL, respectively, for all P < 0.05, t-tests).
Diol/epoxide ratios
To provide insights into possible mechanisms underlying
the increase in individual CYP metabolites in exercise, we
calculated diol/epoxide ratios in the circulation and ana-
lyzed their changes in response to exhaustive exercise and
post exercise. The results are presented in Table 3. Our
ANOVA analysis showed that exercise did not change the
ratios for each substrate class in vivo during and post
exercise. Similar results were found for the individual
metabolites, as shown in Table 4. We also found that the
four classes of epoxy-metabolites are unequally hydrolyzed
to appear in the circulation (Greenhouse-Geisser, P1,
P = 0.001). We found that EEQs are preferentially metab-
olized into their diols (ratio DiHETEs/EEQs at P1,
1.97  0.61) compared to EpOMEs, EETs and EDPs (ra-
tios diols/epoxy-metabolites at P1, 0.34  0.05,
0.47  0.15, 0.15  0.04, respectively) in Table 2. In fact,
the following order of ratios was identified: DiHETEs/
EEQs > DHETs/EETs = DiHOMEs/EpOMEs > DiHDPA/
EDPs (paired t-tests, one-tailed, Bonferroni correction).
This pattern was also found for individual metabolites, as
shown in Table 4. Together the results indicate that 5,6-
DHET, 9,10-EpOME, 5,6-DiHETE, and 17,18-DiHETE are
rather released and accumulated in the circulation during
the hemodynamic and metabolic response in short-term
maximal exercise than result from altered sEH activity.
Discussion
This study is the first documentation that circulating
endogenous n  3 and n  6 CYP mediator levels can be
ª 2019 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
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Table 1. Circulating plasma epoxides and diols in response to exhaustive exercise (n = 6)
Epoxide or diol
(lg/mL)
Time point 1
(rest), P1
Time point 2
(HF 150), P2
Time point 3
(exhaustion), P3
Time point 4
(recovery), P4
Greenhouse–Geisser,
P value
9,10-EpOME 23.45  4.65 25.09  7.06 28.37  7.16 23.60  4.87 0.235
12,13-EpOME 31.90  10.35 35.04  9.16 42.91  12.12 38.97  13.73 Friedman P = 0.029
9,10-DiHOME 7.16  1.52 7.38  1.58 7.24  1.26 6.51  0.89 0.379
12,13-DiHOME 11.06  2.61 11.63  2.84 13.64  4.01 13.00  3.20 0.138
5,6-EET 2.89  0.56 3.29  1.33 3.19  1.22 2.72  0.49 Friedman P = 0.512
8,9-EET 4.33  0.95 4.88  1.91 4.53  1.75 4.00  0.90 0.348
11,12-EET 2.58  0.71 2.92  1.04 2.72  0.97 2.38  0.49 0.384
14,15-EET 3.11  0.94 3.38  1.06 3.11  0.98 3.00  0.76 0.579
5,6-DHET 3.10  0.81 3.12  0.79 3.46  0.92 3.16  0.91 0.009
8,9-DHET 1.83  0.48 1.88  0.42 2.04  0.52 1.93  0.58 Friedman P = 0.108
11,12-DHET 0.55  0.08 0.56  0.05 0.59  0.07 0.53  0.06 0.179
14,15-DHET 0.42  0.06 0.44  0.04 0.48  0.05 0.45  0.05 0.056
5,6-EEQ 0.12  0.04 0.12  0.04 0.12  0.03 0.11  0.03 0.766
8,9-EEQ 0.40  0.09 0.36  0.15 0.35  0.11 0.33  0.09 0.536
11,12-EEQ 0.21  0.08 0.21  0.07 0.19  0.02 0.20  0.03 0.459
14,15-EEQ 0.29  0.10 0.29  0.10 0.28  0.08 0.25  0.08 0.621
17,18-EEQ 0.49  0.16 0.49  0.17 0.44  0.07 0.45  0.09 0.567
5,6-DiHETE 0.99  0.42 1.05  0.52 1.22  0.43 1.08  0.46 0.019
8,9-DiHETE 0.52  0.18 0.51  0.17 0.56  0.19 0.52  0.12 Friedman P = 0.163
14,15-DiHETE 0.26  0.04 0.29  0.08 0.29  0.06 0.23  0.06 0.056
17,18-DiHETE 1.07  0.13 1.02  0.25 1.29  0.23 1.15  0.23 0.029
7,8-EDP 1.65  0.30 1.84  0.78 1.78  0.75 1.53  0.34 0.402
10,11-EDP 1.50  0.26 1.70  0.85 1.57  0.80 1.32  0.36 Friedman P = 0.541
13,14-EDP 0.92  0.15 1.10  0.40 1.03  0.37 0.87  0.11 Friedman P = 0.668
16,17-EDP 1.18  0.18 1.29  0.37 1.26  0.35 1.14  0.15 Friedman P = 0.668
19,20-EDP 1.43  0.38 1.56  0.47 1.61  0.50 1.57  0.64 Friedman P = 0.512
7,8-DiHDPA 0.41  0.14 0.41  0.14 0.49  0.17 0.45  0.11 0.187
10,11-DiHDPA 0.07  0.03 0.08  0.03 0.08  0.03 0.07  0.02 0.182
13,14-DiHDPA 0.05  0.01 0.05  0.01 0.06  0.01 0.05  0.01 0.150
16,17-DiHDPA 0.23  0.05 0.24  0.06 0.30  0.10 0.26  0.08 Friedman P = 0.056
19,20-DiHDPA 0.20  0.06 0.20  0.05 0.22  0.07 0.20  0.06 0.249
5-HETE 19.36  3.59 21.31  6.43 21.57  6.04 19.39  4.46 0.474
8-HETE 8.88  1.45 10.33  3.80 10.13  3.35 8.84  1.94 0.451
9-HETE 12.84  2.85 14.97  6.34 14.15  5.36 12.39  2.70 0.485
11-HETE 19.86  4.24 24.48  10.32 22.67  7.81 18.90  2.94 0.358
12-HETE 19.38  4.83 20.32  6.12 24.16  8.19 27.09  13.27 0.151
15-HETE 10.35  2.43 12.15  6.40 11.54  5.67 9.49  2.34 Friedman P = 0.574
20-HETE 0.22  0.09 0.21  0.09 0.22  0.11 0.20  0.05 0.776
5-HEPE 2.39  0.93 2.43  1.12 2.30  0.68 2.20  0.81 Friedman P = 0.772
8-HEPE 0.71  0.29 0.80  0.37 0.76  0.19 0.71  0.33 0.650
9-HEPE 1.13  0.38 1.23  0.56 1.10  0.37 1.07  0.38 0.683
12-HEPE 1.40  0.43 1.37  0.52 1.47  0.48 1.58  0.61 0.438
15-HEPE 0.79  0.29 0.76  0.23 0.75  0.21 0.71  0.20 0.689
18-HEPE 3.25  0.99 3.51  1.40 3.17  1.08 2.86  0.92 0.393
4-HDHA 4.99  1.10 6.19  2.92 5.74  2.80 4.68  .14 Friedman P = 0.317
7-HDHA 3.15  0.94 3.43  1.45 3.54  1.33 2.99  0.95 0.478
8-HDHA 6.17  1.75 6.77  3.18 6.41  2.34 5.55  1.40 0.492
10-HDHA 3.71  0.92 4.00  1.57 3.93  1.36 3.62  0.66 0.715
11-HDHA 3.88  1.04 4.23  1.85 3.97  1.38 3.63  0.91 0.577
13-HDHA 3.23  0.84 3.71  1.82 3.45  1.60 3.02  0.68 0.526
14-HDHA 10.95  3.13 10.35  2.75 12.05  2.91 14.00  5.70 Friedman P = 0.108
16-HDHA 2.61  0.63 3.05  1.61 2.82  1.41 2.28  0.55 Friedman 0.073
17-HDHA 2.97  1.15 4.22  1.30 4.45  1.20 3.69  0.90 0.097
(Continued)
2019 | Vol. 7 | Iss. 13 | e14165
Page 6
ª 2019 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
The Physiological Society and the American Physiological Society.
Exercise and Circulating Epoxy-Metabolites B. Gollasch et al.
Table 2. Concentrations of individual epoxides plus their respective diols in response to exhaustive exercise (n = 6)
Epoxides or Diols (lg/mL)
Time point 1
(rest), P1
Time point 2
(HF 150), P2
Time point 3
(exhaustion), P3
Time point 4
(recovery), P4
Greenhouse–Geisser,
P value
9,10-EpOME + 9,10-DiHOME 30.20  5.73 33.28  8.39 35.60  8.17 30.11  5.41 0.263
12,13-EpOME + 12,13-DiHOME 42.95  12.17 46.67  10.87 56.56  15.32 51.98  16.48 0.037
5,6-EET + 5,6-DHET 5.98  1.02 6.41  2.08 6.65  2.03 5.88  1.26 0.037
8,9-EET + 8,9-DHET 6.16  1.10 6.77  2.27 6.57  2.23 5.92  1.27 0.021
11,12 EET + 11,12-DHET 3.12  0.68 3.48  1.05 3.31  1.00 2.90  0.49 0.343
14,15-EET + 14,15-DHET 3.53  0.95 3.83  1.07 3.59  0.99 3.45  0.79 0.583
5,6-EEQ + 5,6-DiHETE 1.12  0.43 1.17  0.56 1.34  0.45 1.19  0.48 0.031
8,9-EEQ + 8,9-DiHETE 0.92  0.22 0.87  0.28 0.91  0.27 0.79  0.15 0.260
14,15-EEQ + 14,15-DiHETE 0.55  0.96 0.58  0.15 0.57  0.10 0.48  0.12 0.100
17,18-EEQ + 17,18-DiHETE 1.56  0.14 1.51  0.24 1.73  0.24 1.59  0.28 0.127
7,8-EDP + 7,8-DiHDPA 2.06  0.41 2.25  0.87 2.27  0.89 1.98  0.45 0.413
10,11-EDP + 10,11-DiHDPA 1.57  0.28 1.78  0.87 1.65  0.82 1.38  0.38 0.380
13,14-EDP + 13,14-DiHDPA 0.97  0.15 1.15  0.39 1.08  0.37 0.92  0.11 0.369
16,17-EDP + 16,17-DiHDPA 1.41  0.18 1.53  0.36 1.56  0.36 1.40  0.21 Friedman 0.772
19,20-EDP + 19,20-DiHDPA 1.64  0.41 1.77  0.49 1.83  0.54 1.77  0.70 0.415
Table 1. Continued.
Epoxide or diol
(lg/mL)
Time point 1
(rest), P1
Time point 2
(HF 150), P2
Time point 3
(exhaustion), P3
Time point 4
(recovery), P4
Greenhouse–Geisser,
P value
20-HDHA 8.97  2.34 9.72  4.36 9.68  3.79 8.66  1.83 0.660
21-HDHA 0.38  0.43 0.45  0.50 0.50  0.60 0.50  0.56 Friedman P = 0.958
13-HODE 483.37  111.82 521.66  140.02 529.33  160.11 471.45  115.38 Friedman P = 0.668
Table 3. Ratios estimated using total concentrations of epoxides and diols in response to exhaustive exercise (n = 6)
Epoxides or diols (lg/mL) or Ratios
Time point 1
(rest), P1
Time point 2
(HF 150), P2
Time point 3
(exhaustion), P3
Time point 4
(recovery), P4
Greenhouse–
Geisser,
P value
9,10-EpOME + 12,13-EpOME 54.94  14.25 60.94  14.14 71.28  16.82 62.57  16.78 0.093
9,10-DiHOME + 12,13-DiHOME 18.22  3.85 19.01  4.21 20.88  4.98 19.52  3.66 0.383
Ratio (9,10-DiHOME + 12,13-DiHOME)/
(9,10-EpOME + 12,13-EpOME)
0.34  0.05 0.32  0.06 0.30  0.05 0.31  0.05 0.189
5,6-EET + 8,9-EET + 11,12 EET + 14,15-EET 12.90  3.11 14.47  5.24 13.56  4.85 12.10  2.47 0.407
5,6-DHET + 8,9-DHET + 11,12-DHET  14,15-DHET 5.90  1.35 6.01  1.21 6.58  1.48 6.06  1.51 0.031
Ratio (5,6-DHET + 8,9-DHET + 11,12-DHET +
14,15-DHET)/(5,6-EET + 8,9-EET + 11,12 EET + 14,15-EET)
0.47  0.15 0.44  0.10 0.51  0.10 0.51  0.12 0.461
5,6-EEQ + 8,9-EEQ + 11,12-EEQ + 14,15-EEQ + 17,18-EEQ 1.52  0.43 1.49  0.52 1.39  0.28 1.35  0.30 0.540
5,6-DiHETE + 8,9-DiHETE + 14,15-DiHETE + 17,18-DiHETE 2.84  0.65 2.88  0.80 3.37  0.67 2.92  0.63 0.018
Ratio (5,6-DiHETE + 8,9-DiHETE + 14,15-DiHETE +
17,18-DiHETE)/(5,6-EEQ + 8,9-EEQ + 11,12-EEQ +
14,15-EEQ + 17,18-EEQ)
1.97  0.61 2.08  0.81 2.46  0.50 2.21  0.48 0.237
7,8-EDP + 10,11-EDP + 13,14-EDP + 16,17-EDP +
19,20-EDP
6.68  0.83 7.50  2.38 7.25  2.30 6.43  0.87 0.450
7,8-DiHDPA + 10,11-DiHDPA + 13,14-DiHDPA +
16,17-DiHDPA + 19,20-DiHDPA
0.97  0.25 0.99  0.22 1.15  0.31 1.04  0.23 0.042
Ratio (7,8-DiHDPA + 10,11-DiHDPA + 13,14-DiHDPA +
16,17-DiHDPA + 19,20-DiHDPA)/(7,8-EDP + 10,11-EDP +
13,14-EDP + 16,17-EDP + 19,20-EDP)
0.15  0.04 0.14  0.04 0.16  0.04 0.16  0.02 0.357
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modulated by short-term exhaustive exercise in humans.
In particular, we found that the circulating levels of the
CYP metabolites 12,13-EpOME/DiHOME, 5,6-EET/
DHET, 5,6-EEQ/DiHETE, and 17,18-EEQ/DiHETE
increased in response to maximal exercise. We found that
these changes are unlikely related to altered sEH activity,
which preferentially metabolizes other CYP expoxy-
metabolites (i.e., EEQs) into their diols (Fischer et al.
2014). We did not detect changes in specific mediators
derived from the LOX and CYP omega/(omega-1) path-
ways in response to exhaustive exercise. The extent to
which beneficial cardiovascular effects of n  3 polyun-
saturated fatty acids (PUFAs) and cardiovascular exercise
are mediated by increased levels of epoxides derived from
the CYP monooxygenase pathway remains to be explored.
EETs/DHETs
Endothelial cells are reservoirs of EETs and the primary
source of plasma EETs, which are esterified to the phos-
pholipids of lipoproteins (Jiang et al. 2010; Jiang et al.
2011; Schunck et al. 2017). On release, EETs affect vascu-
lar tone and blood pressure, produce pro-fibrinolysis and
reduce inflammation (Jiang et al. 2010; Jiang et al. 2011;
Jiang et al. 2012). DHETs were initially thought to be
inactivation products of EETs, but several recent studies
indicate that, like EETs, they produce vasodilation (Her-
cule et al. 2009) and activate smooth muscle BK channels
(Lu et al. 2001). The mechanisms of how epoxides and
diols are released from the tissues and eventually become
constituents of circulating lipoproteins are largely
unknown, making it difficult to explain these findings.
Cells preferentially release DHETs while storing the EETs
(Roman 2002), suggesting that certain diols might be
overrepresented in the circulation compared with the
epoxide/diol ratios in the tissues where these metabolites
were primarily produced (Fischer et al. 2014). In this
study, we were able to demonstrate that maximal tread-
mill exercise affects plasma EET/DHET status, in particu-
lar by increasing 5,6-DHET levels, which could contribute
to cardiovascular responses and hemodynamics. Of note,
submaximal testing on a bicycle ergometer has been
found to increase plasma levels of 14,15-DHET (Giordano
et al. 2011). Our data are in agreement with the idea that
EETs/DHETs are attractive mediator signals for skeletal
muscle blood flow regulation in humans because they can
act as potent vasodilators (Campbell and Fleming 2010)
and their circulating levels are increased during exercise.
These properties could be essential to counteract the
vasoconstrictor effects of concurrent increases in muscle
sympathetic nerve activity and circulating vasoconstrictor
substances during exercise.
12,13-EpOME
We observed increases in plasma concentrations of 12,13-
EpOME during maximal exercise. However, 9,10-EpOME
and 12,13-EpOME (leukotoxins A and B) were initially
described to be produced by neutrophils during the
oxidative burst to combat bacterial infection (Thompson
and Hammock 2007). These mediators are converted by
sEH into DiHOMEs (Fig. 1), which suppress the neu-
trophil respiratory burst (Thompson and Hammock
2007). Recent findings suggest that both EpOMEs (with
Table 4. Ratios estimated using individual concentrations of epoxides and their diols in response to exhaustive exercise (n = 6)
Ratios
Time point 1
(rest), P1
Time point 2
(HF 150), P2
Time point 3
(exhaustion), P3
Time point 4
(recovery), P4
Greenhouse–
Geisser, P value
9,10-DiHOME/9,10-EpOME 0.314  0.054 0.292  0.046 0.260  0.038 0.281  0.040 0.169
12,13-DiHOME/12,13-EpOME 0.357  0.070 0.341  0.076 0.323  0.062 0.347  0.067 0.279
5,6-DHET/5,6-EET 1.100  0.330 0.994  0.172 1.135  0.246 1.160  0.257 0.444
8,9-DHET/8,9-EET 0.439  0.136 0.413  0.110 0.475  0.115 0.491  0.121 0.388
11,12-DHET/11,12-EET 0.228  0.080 0.213  0.079 0.241  0.083 0.229  0.046 0.749
14,15-DHET/14,15-EET 0.147  0.046 0.144  0.050 0.168  0.048 0.154  0.024 0.401
5,6-DiHETE/5,6-EEQ 8.617  3.927 8.512  2.270 10.093  2.401 9.698  2.820 0.370
8,9-DiHETE/8,9-EEQ 1.318  0.499 1.551  0.591 1.643  0.549 1.449  0.510 0.439
14,15-DiHETE/14,15-EEQ 0.977  0.418 1.103  0.505 1.152  0.520 0.957  0.349 0.512
17,18-DiHETE/17,18-EEQ 2.441  0.954 2.428  1.401 2.972  0.739 2.624  0.575 0.380
7,8-DiHDPA/7,8-EDP 0.247  0.072 0.234  0.060 0.287  0.076 0.295  0.018 0.226
10,11-DiHDPA/10,11-EDP 0.049  0.013 0.048  0.013 0.055  0.016 0.055  0.008 0.582
13,14-DiHDPA/13,14-EDP 0.055  0.017 0.050  0.015 0.058  0.014 0.057  0.005 0.631
16,17-DiHDPA/16,17-EDP 0.203  0.060 0.201  0.072 0.248  0.090 0.226  0.045 0.352
19,20-DiHDPA/19,20-EDP 0.146  0.039 0.134  0.037 0.144  0.038 0.132  0.021 0.545
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12,13-EpOME being more potent) can exhibit both car-
diodepressant (Sugiyama et al. 1987; Fukushima et al.
1988; Siegfried et al. 1990) and vasoactive properties, for
example, by increased endothelial NO and O(2)(*-) pro-
duction (Okamura et al. 2002). Increased cardiac tissue
levels of DiHOME may cause detrimental effects on
postischemic cardiac function (Chaudhary et al. 2013;
Bannehr et al. 2019). Therefore, it is unclear whether the
observed increases in plasma levels of 12,13-EpOME in
our study reflect a physiological cardiovascular response
upon exercise or may potentially contribute to detrimen-
tal cardiovascular effects. Interestingly, elite and nonelite
athletes have an increased incidence of sudden death (Del
Rio-Santiago et al. 2012; Bohm et al. 2016), which has
been attributed to a low omega-3 index, that is, low red
blood cell EPA/DHA status (von Schacky et al. 2014).
Our study involved nontrained subjects. It is unknown
whether increases in plasma levels of 12,13-EpOME are
also observed in trained athletes and in extreme endur-
ance training. Nevertheless, our study indicates that circu-
lating CYP products of LA, that is, EpOMEs, deserve
special attention in extreme exercise. Our data also indi-
cate that these metabolites could also affect hemodynam-
ics in these conditions. Of note, we found that the
majority of CYP and LOX metabolites measured were not
affected, suggesting that these metabolites are unlikely to
play a role in this scenario.
5,6-DiHETE and 17,18-DiHETE
We observed increases in plasma concentrations of 5,6-
DiHETE and 17,18-DiHETE during maximal exercise.
These mediators are produced by hydrolysis of 5,6-EEQ
and 17,18-EEQ, respectively (Fig. 1). While the putative
biological function(s) of 5,6-DiHETE and 17,18-DiHETE
have not received much attention, 17,18-EEQ has been
identified as potent vascular BKCa channel activator and
vasodilator, which is more potent that EETs (Lauterbach
et al. 2002; Hercule et al. 2007). Inhibition of sEH is a
potential approach for enhancing the biological activity of
EETs (Spector and Kim 2015). However, presumably
higher levels of EETs in blood and tissue in vivo may
have also detrimental cardiovascular side effects
(Gschwendtner et al. 2008; Hutchens et al. 2008; Wutzler
et al. 2013). We have no evidence that the higher levels of
5,6-DHET, 5,6-DiHETE, and 17,18-DiHETE during maxi-
mal exercise result from sEH enzyme activation. Based on
our calculations of diol/epoxide ratios, this is rather unli-
kely. Furthermore, the levels of other DHETs and
DiHETEs, DiHOMEs, and DiHDPAs did not vary during
maximal exercise. The mechanisms of how epoxides and
diols are released from the tissues and eventually become
constituents of circulating lipoproteins are largely
unknown, making it difficult to explain these findings
(Fischer et al. 2014). Nevertheless, the function and
pathophysiological roles of circulating 5,6-DiHETE and
17,18-DiHETE has yet to be integrated into a physiologi-
cal and pathophysiological context. This is particularly
important since drugs that mimic 17,18-EEQ have been
developed and are viewed as novel drug candidates that
may overcome limitations of dietary EPA/DHA supple-
mentation for cardiovascular health benefits (Schunck
et al. 2017).
Exercise protocol considerations and
limitations
The modified Bruce cardiac stress test was used to ensure
that all runners were able to complete a similar highest
intensity workload (13.50  1.97 METs) concomitant
with robust and significant short-term increases in hemo-
dynamics (heart rate and blood pressure) without fatigu-
ing. For consistency, we also used an intermediate
workload (10.00  1.90 METs, P = 0.0009, t-test) reach-
ing a heart frequency of 150 or more beats per minute to
ensure that all subjects could complete the test with pro-
found increases in heart rate and blood pressure without
fatiguing. Our clinical data (Fig. 3) show that the exercise
protocol caused the expected hemodynamic changes in
our study.
We obtained venous blood from an arm vein, although
the source of plasma lipid mediators, if modified from
exercising muscle and its vasculature, suggests that the leg
would provide a different measure. However, blood sam-
ples were taken from the arm vein because of the great
difficulty associated with obtaining blood from a vein in
dynamically contracting leg muscles. Therefore, stronger
effects may have been present in the venous effluent of
the exercising muscle (Giordano et al. 2011). We studied
effects of maximal short-term exercise, but not endurance
exercise, which may also lead to different results.
Conclusions
To the best of our knowledge, we conducted the first
study on the impact of acute exercise on individual circu-
lating fatty acid epoxy-metabolites derived from the CYP
monooxygenase pathway and specific mediators derived
from the LOX and CYP hydrolase pathways. Lipid media-
tor profiling was performed on venous blood taken from
healthy individuals undergoing maximal treadmill exercise
using the standard Bruce protocol to induce strong and
robust hemodynamic and metabolic changes (Bruce et al.
1973; Trappe and Lollgen 2000). We confirmed our
hypothesis that individual epoxy-metabolites are modu-
lated in response to short-term exhaustive exercise (with
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exception of EEQ and LOX metabolites). The changes
concurred with profound effects on heart rate, blood
pressure, and lactate. Our results indicate that individual
circulating CYP epoxy-metabolite status, particularly
12,13-EpOME/DiHOME, 5,6-EET/DHET, 5,6-EEQ/
DiHETE, and 17,18-EEQ/DiHETE status, may affect the
cardiovascular response in short-term maximal exercise.
Future research is required to determine the contribution
of the individual epoxy-metabolites to cardiac perfor-
mance and regulation of coronary and/or skeletal-muscle
blood flow in health and cardiovascular disease.
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